Doublet mutations in cancer are not well studied. We find that allelic somatic doublet mutations are present at high frequency in the epidermal growth factor receptor (EGFR) tyrosine kinase (TK) domain in lung cancers. When doublets from the literature are added, a total of 96 doublets are available for analysis. The frequency of doublets overall is 6%, which is sevenfold greater than that observed in normal tissue in mouse. All characterized doublets are allelic, and silent mutations occur rarely. About half of all doublets contain one or two of 12 distinct missense mutations at five amino acids: E709, G719, S768, T790 and L861. The mutations at these five amino acids are seldom reported as singlets. Moreover, when the common L858 target is included, more than one-third of EGFR doublets are one of five specific missense pairs: G719/E709, G719/S768, G719/L861, L858/E709 and L858/T790. Structure suggests function: The data imply that most EGFR doublets are NOT consistent with a 'driver and passenger' mutation mechanism. EGFR doublets are highly skewed relative to singlets, consistent with functional selection of two individually suboptimal mutations that, in combination, have enhanced oncogenic potential.
Introduction
Epidermal growth factor receptor (EGFR) (NM_005228.3) is a 170 kDa tyrosine kinase (TK) receptor that dimerizes and initiates multiple signaling pathways associated with cell proliferation, differentiation, migration and metastasis, anti-apoptosis and angiogenesis (Arteaga, 2002) . EGFR is an attractive therapeutic target because EGFR mutations associated with response to TK inhibitors (gefitinib or erlotinib) are identified in 10-40% of patients (depending on ethnicity) with non-small cell lung cancer (NSCLC) (Lynch et al., 2004; Paez et al., 2004; Shigematsu and Gazdar, 2005a) . Cells with EGFR mutations are relatively resistant to apoptosis induced by conventional chemotherapeutic drugs and radiation therapy, but undergo extensive apoptosis after treatment with gefitinib or erlotinib (Shintani et al., 2003; Sordella et al., 2004) . EGFR mutations mainly aggregate in two hot spot regions, around codons 746-750 in exon 19 (deletion, 32%) and codon 858 in exon 21 (missense, 38%), while two-thirds of 131 unique mutations have been reported only once and account for only 11% of reported mutations (Gu et al., 2007) . Herein, we report that the frequency of doublets in the EGFR gene is much higher than that observed in normal mouse tissue (Buettner et al., 2000; Hill et al., 2004) . The doublets in EGFR differ in several important ways, consistent with selection for altered EGFR activity underlying most of the observed EGFR doublets in lung cancer. The selection for two structural mutations favoring certain amino-acid sites seldom mutated in cases with a single mutation has implications for EGFR structure and function and demonstrates the ability of cancers to accumulate more than one adaptive structural change.
Results
Four doublet EGFR mutations in 25 lung cancers from our sample set of 78 patients Mutational analysis of 78 lung cancers defined 25 mutations in the EGFR gene kinase domain (32%) ( Table 1; Supplementary Table S-1) . Five novel mutations (not reported in the literature) were found, four of which were in doublets and one in a singlet (bold face in Table 1 ). They include two in-frame insertions, one in-frame deletion in the highly conserved hot spot region (MIDIs), one highly conserved missense mutation and one intronic deletion of unknown significance. Normal lung tissue was available in 23 of 25 patients with mutations. In all cases, the mutation was not found in normal tissue, demonstrating a somatic origin. In total, 60% of mutations were balanced heterozygotes, while 32% of mutations showed mutant allele dominant (MAD) chromatograms (Supplementary Figure S-1 and Supplementary Text) consistent with preferential gene amplification of the mutated allele, as described in previous reports (Takano et al., 2005; Shigematsu et al., 2005b) . Review of the microdissected samples showing MAD confirms that the overwhelming number of cells were morphologically tumor cells, which makes the alternative interpretation of 10-30% contaminating wildtype cells unlikely. Two cases showed mutant allele only (MAO) chromatograms, consistent with either dramatic amplification of the mutated allele or loss of heterozygosity or both (Ma et al., 2007) . There was no case with a wild-type allele dominant (WAD) chromatogram.
Three of the four doublets in the sample were close enough to co-amplify and analyse by allele-specific PCR or by subcloning and sequencing, proving that the mutations in these doublets are on the same allele (Supplementary Figure S- 2).
EGFR doublets occur at high frequency and differ in spectrum and pattern from singlets Analysis of the literature confirms a high frequency of EGFR somatic doublets in lung cancer. Our results and a total of 66 publications describing EGFR mutations in lung cancer reveal 1525 singlets and 96 doublets among 6874 patients. Doublets account for 6% of mutations (Supplementary Table S -2) . This is high relative to the spontaneous frequency of doublets in normal mouse tissues (0.8%) or human HPRT somatic mutations in lymphocytes (0.3%) (Hill et al., 2004) . In total, 80 of the 192 mutations (42%) found in doublets are not found in singlets (www.EGFR.org). In total, 65 of 96 doublets (68%) contain at least one mutation not found in singlets. Just one doublet (1%, 1 of 96) consists of two common mutations (L858R/E746_A750del). Missense mutations at five amino acids (E709, G719, S768, T790 and L861) are uncommon among singlets (aggregate frequency of 3.7%, 56 of 1525), but highly overrepresented in doublets: 50 of 96 doublets contain at least one of these missense mutations (52%) ( Table 2,  Supplementary Table S -2) . Note that six different amino acid changes at E709 and three different amino acid changes at G719 are observed. If the common L858R mutation is added, more than one-third of all the doublets found before therapy occur at five amino-acid pairs in decreasing order: E709/G719 (nine pairs); E709/ L858R (nine pairs); G719/S768I (eight pairs); L858R/ T790M (five pairs); G719S/L861Q (three pairs) (Figure 1 ). The six amino acids commonly appearing in EGFR doublet mutations (E709, G719, S768, T790, L858 and L861) are conserved during billions of years of evolution (Supplementary Table S-3). These amino acids are unchanged in nine mammals, one marsupial, frog, five fish and Drosophila, with the only exception being E709, which is conservatively substituted by D709 in Drosophila. Additionally, all amino acids appearing in the 96 doublets except two (L703, R803) are highly evolutionarily conserved in the critical functional kinase domain and putatively alter function.
All characterized doublets are on the same allele Our sequencing of three doublets revealed that all were allellic (bold in Table 1 ). Among 92 doublets in our review of the literature, all 13 characterized heterozygous doublets are also allelic somatic mutations (underlined in Supplementary Table S-2) (Tam et al., 2006; Yokoyama et al., 2006) . Bell et al. (2005) also found second somatic mutations (L858R, L747-T751del and G719A) that are in cis with a germline mutation (T790M) in a family with multiple cases of NSCLC. This is consistent with an in cis effect, that is, an effect that requires that both structural changes be within the same molecule. EGFR doublets in lung cancer differ from doublets in normal mouse tissue The mutation pattern in EGFR doublets differs dramatically from singlets (Table 3a) . Differences remain even when the five common missense doublets are removed (Table 3b ). In contrast, the patterns of spontaneous doublets and singlets in normal tissues are similar in the lacI transgene of Big Blue mice (Buettner et al., 2000; Hill et al., 2004) . While specific doublets reoccur frequently in the EGFR gene, no recurring doublets were found in the lacI gene. When the doublet mutation pattern is classified, 20% of lacI doublets have a silent change vs only 2% of EGFR doublets in lung cancers (P ¼ 0.0005) ( Table 4 ).
Response to tyrosine kinase inhibitors is similar
Outcome data for tumors with doublet mutations were compared to that of tumors with singlet mutations. Outcome data are available for 77% of the patients with doublets (Supplementary Table S 
Discussion
An 'astrogenetic' analysis reveals a high frequency of doublets due to a driver/driver mechanism 'Astrogeneticists' utilize mutation frequency, spectrum and pattern to make inferences about in vivo mutagenesis, which cannot be observed directly, in a manner similar to astronomers who utilize electromagnetic frequency, spectrum and pattern to make inferences about the universe that cannot be observed directly. This astrogenetic analysis of EGFR doublets in lung cancer shows that EGFR doublets are elevated more than sevenfold relative to spontaneous doublet mutations in normal mouse and human tissues. The reason is unclear. Selection, hypermutability or both may be responsible. The data are consistent with sequential selection for doublets of high oncogenic potential from individual somatic mutations that may have low or moderate oncogenic potential (see also below). It is unclear why E709, G719, S768, L861 and T790 are frequent in doublets but uncommon in singlets. At least for E709 and G719, multiple amino-acid substitutions are observed in doublets. Some of these aminoacid substitutions have never been seen in singlets. Since EGFR can stimulate cell growth, cells with an activityenhancing mutation preferentially replicate, predisposing to serial selection of cell clones that further enhance replication and oncogenesis. Amino-acid substitutions at E709, G719, S768, T790 and L861 may produce suboptimal oncogenic activation mutations as suggested by (1) their low frequency in lung cancers with singlet mutations (Gu et al., 2007) Chen et al., 2006) . Thus, there is a selective advantage of a complementary second allelic mutation that may more fully activate EGFR, resulting in the frequent recurrence of such doublet pairs. Of the 96 EGFR doublets, 99% contain at least one putative suboptimal mutation; only one doublet (1%) contains two common mutations (L858R/E746_A750del), either of which is capable of oncogenesis as a singlet.
The frequency of silent mutations is consistent with the baseline level of doublets observed in other systems About 22% of the second mutations in doublets are expected to be silent if they are 'passenger' mutations (Sommer and Cohen, 1980) . This fraction is observed in the p53 gene and in genomic surveys of somatic mutations in cancers (Strauss, 1997 (Strauss, , 2000 Davies et al., 2005; Greenman et al., 2007) . The 10 silent mutations (20%) observed in spontaneous doublets in Big Blue mice predict 45 passenger mutations, consistent with most of the 51 observed doublets containing a driver and a passenger mutation (Buettner et al., 2000; Hill et al., 2004) .
In contrast, only two silent mutations occur in 96 EGFR doublets, predicting nine (9%, 9 of 96) doublets containing a passenger mutation. Thus, about 91% (87 of 96) of doublets in EGFR consist of two driver mutations. It is noteworthy that the predicted minority of EGFR doublets due to driver plus passenger mutations in lung cancer (0.6%, 9 of 1621) is similar to the predicted frequency of lacI passenger mutations in normal mouse tissue (0.7%, 45 of 6145), representing the endogenous baseline level of doublets.
The frequency of somatic doublets in other genes in human cancers generally seems to be much lower. For example, Sjoblom et al. (2006) sequenced 13 023 coding sequences in 11 colon cancers and 11 breast cancers. An analysis of mutations in this data determined that 0.9% of 2147 somatic mutation events are doublets with mutation spacing within 10 kb and often much closer (manuscript in preparation), consistent with the observed frequency of 0.8% (lacI) in normal mouse tissues (Buettner et al., 2000; Hill et al., 2004) and the predicted endogenous frequency of 0.6% (EGFR) in lung cancers. The great majority of these are passenger mutations unrelated to the cancer phenotype (Sjoblom et al., 2006) . Thus, most doublets in colon and breast cancers are putative passenger and passenger mutations.
In summary, analysis of three different systems demonstrates that there are three different combinations of doublets mechanistically arising by driver/driver (EGFR), driver/passenger (lacI) and passenger/ passenger pairs (Sjoblom et al., 2006) . Driver/Driver pairs are consistent with functional studies Functional assays for the five amino acids present in half of all doublets (E709, G719, S768, L861, T790) find that mutant EGFRs have alterations in baseline tyrosine phosphorylation and/or responses to epidermal growth factor (EGF) stimulation compared to wild-type EGFR Mulloy et al., 2007; Vikis et al., 2007) (Supplementary Table S -3) . It is intriguing that missense changes for the first four amino acids listed above result in stronger baseline phosphorylation at tyrosine 1045 than that observed in the common mutations (15 bp deletion), as well as increased phosphorylation induced by EGF. E709G and G719S also lack EGF-induced receptor downregulation. Analysis of a doublet (L858R/ E709G) that is seen four times in patients (IDnos. 13-16 in Supplementary Table S-2) provides evidence for an additive effect relative to the singlet L858R and E709G mutations in the absence of EGF stimulation . Synergistic effects are also observed for the L858R/T790M doublet seen five times in patients (IDnos. 27-31 in Supplementary Table S-2) (Godin-Heymann et al., 2007; Mulloy et al., 2007; Regales et al., 2007) and E746_A750del/T790M (Godin-Heymann et al., 2007) . Thus, the inference from our data that doublets generally arise from additive events is supported by the in vitro functional studies that are available.
A continuous colorimetric in vitro kinase assay (Yun et al., 2007) demonstrates that the catalytic activity in the G719S mutant is approximately 10-fold more active than that of wild-type EGFR, while L858R is 50-fold more active than that of the wild type. Moreover, the crystal structures of L858R and G719S reveal that the mutations activate the kinase by destabilizing the inactivated conformation. An in cis effect in doublets may occur if the doublets synergistically activate the TK domain through disrupting the autoinhibitory interaction of residues. The observation that the doublets are allelic and not compound heterozygotes is consistent with this model. The functional analyses for structural changes in doublets complement the astrogenetic analysis and support our conclusion that functional selection of two individually suboptimal mutations may occur, producing a cell with enhanced oncogenic potential.
Testable model
Analysis of doublet mutation frequency, pattern and spectrum suggests that most doublets arise by a simple model: sequential selection of suboptimal mutations. The first mutation is sufficient to produce a micro tumor, which is then replaced by a clone with a doublet in cis that has optimal activity. Abbreviations: EGFR, epidermal growth factor receptor; Si, Silent mutation; St, Structural changes including missense, nonsense, and MIDIs.
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The model can be tested in vitro and in vivo by determining if the doublets are more active than either of the singlets in vitro or in vivo. The kinetics of tumorigenesis can be determined in transgenic knock-in mouse lines expressing mutant EGFRs with one of the singlet mutations compared to those with an in cis doublet in EGFR. A transgenic mouse line with the same doublet expressed in trans would provide a control to demonstrate the necessity of in cis mutations for enhanced oncogenesis.
Three recent reports support these predictions. In one study, two patients with a T790M germline mutation in a family with multiple lung cancer cases at age 50 or older were found to have a somatic second mutation (L858R (2), L747-T751del and G719A) in cis with the germline mutation in four of six primary lung tumors (Bell et al., 2005) . In this case, the T790M germline mutation may have caused subtle alterations in EGFR function and may have further enhanced the effect of other activating mutations in the same molecule.
In a second study, bitransgenic mice with EGFR containing the in cis doublet L858R/T790M had a dramatically shorter latency for developing lung tumors than transgenic mice with T790M alone (B17 vs B32 weeks, respectively) (Regales et al., 2007) . Unfortunately, the time course of oncogenesis in transgenic mice with the L858R singlet was not provided.
In the third study, NIH3T3 cells stably expressing EGFR containing the doublets T790M/L858R and T790M/E746_A750del or the individual singlet mutations were injected into nude mice. Cells expressing either doublet pair gave rise to large tumors within 2 weeks in six of six inoculations, whereas cells expressing the singlets L858R or E746_A750del produced similar tumors only after 3 weeks in all six and all four inoculations, respectively. Cells expressing the singlet T790M produced small tumors in only two of six inoculations, and cells with wild-type EGFR did not produce any tumors (Godin-Heymann et al., 2007) . Thus, the doublet-containing EGFR mutants had increased oncogenic activity relative to wild-type EGFR and EGFR single mutants.
Conclusions
In this study, we have described four doublets among 25 mutations in the EGFR gene kinase domain from a set of 78 lung cancer patients. In a meta-analysis of 96 doublets reported herein and in the literature, we found the frequency of doublets to be 6%, far greater than that observed in normal somatic tissue in mouse. More than one-third of the doublets are one of five specific missense pairs, often including mutations that are uncommon as singlets. Analysis of the mutation frequency, pattern and spectrum suggests that the great majority of the doublets are driver/driver mutations, rather than the driver/ passenger mutations found more commonly in other systems. This is consistent with a model in which an initial structural change of low oncogenic potential results in proliferation, which may be followed by a second structural change. The combination of the two changes in cis results in cells of high oncogenic potential.
Materials and methods

Samples
Tumor samples were obtained in the last 2 years from 78 patients with primary lung cancer who underwent curative pulmonary resection or diagnostic biopsy including bronchoscopy and needle biopsy. EGFR mutational analysis was requested for guiding clinical treatment using TK inhibitors (gefitinib or erlotinib). Tumor tissues are routinely fixed by formalin and embedded into paraffin blocks including primary or metastatic tumor. To exclude PCR artifacts caused by formalin fixation, at least two areas with >80% of tumor component were marked on the reference slide by a pathologist. Tumor cells from both areas (about 100-2000 cells) were scraped by manual microdissection and DNAs from each area were extracted for EGFR mutational analysis (Saldivar et al., 2006) .
Molecular analysis of lung cancer specimens
The first four exons (exons 18-21) of the TK domain (exons 18-24) in the EGFR gene (NM_005228.3), where almost all EGFR mutations have been reported (Shigematsu and Gazdar, 2005a) , were amplified through first-round PCR or nested-PCR based on our reported protocol (Supplementary Table S-5) (Saldivar et al., 2006) . The PCR mixtures consist of 10 mM Tris-HCl (pH: 8.3, 25 1C), 50 mM KCl, 1.5 mM MgCl 2 , 5 mM primers, 200 mM dNTP, 0.1 mg/ml bovine serum albumin, 0.5 U AmpliTaq Gold (Applied Biosystems, Foster City, CA, USA) and 2ml digested DNA in a total volume of 25ml. The cycling conditions were 94 1C for 30 s, 55 1C for 30 s and 72 1C for 1 min, for a total of 40-45 cycles. In addition, 94 1C for 10 min was used for the initial denaturation and 72 1C for 7 min for the last extension. Two independently extracted DNAs were simultaneously amplified with a negative control. All sequencing reactions were performed in both the sense and antisense directions with nested PCR primers, and all mutations were confirmed by two independently derived PCR products. Once EGFR mutations were identified, DNA isolated from paired normal tissues (blood or lung tissue lymphocytes located as far as possible from tumor cells) was amplified and sequenced to verify the EGFR alteration as a somatic mutation. Subclones of PCR products using TOPO TA Cloning kit (Invitrogen Life Technologies, Carlsbad, CA, USA) or PASA (Sommer et al., 1992) were utilized to determine whether EGFR doublets were located on the same allele.
For preliminary EGFR gene dosage analysis, EGFR mutations were divided into three patterns in terms of the proportion of mutant alleles in the sequence chromatogram: MAD (the ratio of mutant allele to wild-type allele X2:1), WAD (the ratio of mutant allele to wild-type allele p0.5:1) and balanced heterozygous (BH) (the ratio of mutant allele to wild-type allele between 0.5:1 and 2:1).
Statistical analysis
In order to investigate the characteristics of doublets, EGFR mutations mostly identified by sequencing were collected from 66 published papers and the EGFR mutation database was updated (www.EGFR.org). Mutation patterns and other categorical count distributions were tested for significant differences by analysis as unordered R Â C contingency tables using the 'Fisher-Freeman-Halton' test implemented by the StatXact statistical analysis software package (CYTEL Software Corporation, Cambridge, MA, USA).
Terminology and abbreviations
Mutation spectrum The relative frequencies of mutations at specific sites.
Mutation pattern The relative frequencies of different types of mutation, for example, C to T transitions vs T to C transitions.
Singlet A single mutation identified in a mutant (Hill et al., 2004) .
Tandem-base mutation (TBM) A mutation that results in base changes at adjacent nucleotides (Buettner et al., 1999; Hill et al., 2003) .
Doublet
The double mutations in the EGFR gene occur in exons 18-21 spanning about 18 kb of genomic DNA.
MIDI Microinsertion, deletion, or indel (p50 bp).
Mutant allele dominant (MAD) Sequence chromatogram in which the peak height and area of the EGFR mutant allele is at least twofold greater than that of the wild-type allele in both the sense and antisense directions.
In memory of Harold Z. Sommer, 1921 Sommer, -2000 , lung cancer fatality.
